PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New study finds digoxin safe despite recent reports

Evidence lacking that digoxin increases mortality

2013-04-16
(Press-News.org) CHICAGO --- A study published today in the European Heart Journal found no evidence that digoxin increases mortality in patients with atrial fibrillation (AF), the opposite of results just published by another group in the same journal analyzing the same data.

Older patients with AF also often have heart failure, and digoxin is approved to treat both conditions. AF is the most common kind of cardiac arrhythmia, an electrical malfunction that throws off the heart's rhythm and pumping rate. It may cause no symptoms or cause some patients to faint, but is seldom fatal. Heart failure, a gradual weakening of the heart's pumping strength, contributes to 280,000 U.S. deaths each year.

Both the earlier study that found digoxin increases mortality in AF and the study published today were re-analyses of data first collected as part of a clinical trial called Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) in 2002. The recent study that found digoxin increases mortality used an approach called "time-varying treatment," where patients who continued to receive digoxin over 3.4 years as part of the follow-up to AFFIRM were compared to those who did not.

According to current study, this "time-varying treatment" technique produced misleading results. By analyzing data from sicker patients who required continued digoxin treatment over the long term, it inadvertently introduced bias in its analysis of digoxin-related mortality.

"Digoxin is recommended by major national guidelines for use in heart failure and atrial fibrillation," said Mihai Gheorghiade, M.D., lead author of the study and professor of medicine and of surgery at Northwestern University Feinberg School of Medicine. "It is an inexpensive drug that is generally well tolerated at low doses, and there is no reason to question its usefulness or reassess its safety. We need to remember that although digoxin has been used for over two centuries, it was approved by the FDA in the late 1999s under its strict guidelines for new drug approval based on its safety and efficacy data from multiple randomized clinical trials. So, we are not talking about a new or unsafe drug when we talk about digoxin."

To test the safety of digoxin, the current authors used AFFIRM patient data to assemble a group found to be similar based on 59 characteristics, including age, sex, race, other conditions beside AF (including heart failure) and other medications. Researchers then divided this pool of similar patients into two groups, one that had received digoxin therapy and a second that had not.

The study team found that during the 3.4 years of follow-up, 14 percent of patients receiving digoxin and 13 percent of patients not getting it died. This difference is well within the study's margin of error and, in practical terms, represents no increase in mortality associated with digoxin (hazard ratio, 1.06; 95% confidence interval {CI}, 0.83.37; P=0.640). Among matched patients, digoxin was also not associated with all-cause hospitalization (hazard ratio, 0.96; 95% CI, 0.85.09; P=0.510) or arrhythmias (hazard ratio, 0.90; 95% CI, 0.37.23; P=0.827).

"Heart failure is the only other condition for which digoxin is used, so many of the patients who continued digoxin in the AF clinical trial also had heart failure," said Ali Ahmed, M.D., professor in the divisions of Gerontology, Geriatrics, & Palliative Care and Cardiovascular Disease within the School of Medicine at the University of Alabama at Birmingham (UAB), and the new study's senior author. "You cannot conclude that a drug kills more people without considering whether or not the drug is prescribed for a deadly condition."

The authors conducted the study out of concern that older patients might be deprived of digoxin, which can be helpful in treating AF. They worried that the perception that digoxin increases mortality in AF might gain traction and extend to the treatment of heart failure.

Ahmed recently demonstrated that digoxin could reduce by 34 percent the chances that heart failure patients will be admitted to the hospital within 30 days of first taking it. Preventing frequent admissions is national priority, as the Centers for Medicare and Medicaid Services (CMS) penalized thousands of hospitals in 2012 for above average 30-day readmission rates in patients with pneumonia, heart attack or heart failure.

One in five Medicare recipients is readmitted within 30 days at an annual national cost of $17 billion. Heart failure is the most common culprit. Digoxin is known to reduce acute heart failure symptoms like shortness of breath, which can send people racing back to emergency rooms.

The current debate over the digoxin comes at the end of a decline in use since it failed to lower mortality in an original clinical trial. Research in recent years, however, has shown that digoxin is the only drug in its class (positive inotropes) that does not increase mortality at the traditional dose, and that it may block neurohormone systems like beta blockers or ACE inhibitors. This may explain study results suggesting that low-dose digoxin not only reduces the risk of hospitalization, but may also reduce the risk of death.

In a final note, the current study authors said the scientific community has for years been urging sponsors of large clinical trials for more transparency and data sharing. The National Heart, Lung and Blood Institute (NHLBI) has been a leader in this regard, establishing the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), which has made available the public-use copy of the AFFIRM data that enabled the study authors to challenge the conclusions of the previous study.

### Gheorghiade disclosed consulting relationships with industry, detailed in the journal article.

The original AFFIRM study was supported by the National Heart, Blood and Lung Institute of the National Institutes of Health and Ahmed's work by NHLBI grants (R01-HL085561, R01-HL085561-S and R01-HL097047).


ELSE PRESS RELEASES FROM THIS DATE:

NREL survey shows dramatic improvement in B100 biodiesel quality

2013-04-16
The latest national survey of 100% biodiesel (B100) "blend stock" samples by the U.S. Department of Energy's National Renewable Energy Laboratory (NREL) found that 95% of the samples from 2011-12 met ASTM International fuel quality specifications. The ASTM standards serve as guidelines for industry and are designed to ensure quality at the pump for consumers – along with reliable operation of the nation's vehicles powered by biodiesel blends. "The survey showed a major improvement over results from previous years," NREL Senior Chemist Teresa Alleman said. "In our 2007 ...

Lawrence Livermore scientists discover new materials to capture methane

2013-04-16
Scientists at Lawrence Livermore National Laboratory (LLNL) and UC Berkeley and have discovered new materials to capture methane, the second highest concentration greenhouse gas emitted into the atmosphere. Methane is a substantial driver of global climate change, contributing 30 percent of current net climate warming. Concern over methane is mounting, due to leaks associated with rapidly expanding unconventional oil and gas extraction, and the potential for large-scale release of methane from the Arctic as ice cover continues to melt and decayed material releases methane ...

NREL and Stanford team up on peel-and-stick solar cells

2013-04-16
It may be possible soon to charge cell phones, change the tint on windows, or power small toys with peel-and-stick versions of solar cells, thanks to a partnership between Stanford University and the U.S. Department of Energy's National Renewable Energy Laboratory (NREL). A scientific paper, "Peel and Stick: Fabricating Thin Film Solar Cells on Universal Substrates," appears in the online version of Scientific Reports, a subsidiary of the British scientific journal Nature. Peel-and-stick, or water-assisted transfer printing (WTP), technologies were developed by the ...

When a KISS (1) goes bad

2013-04-16
VIDEO: Moshmi Bhattacharya, Ph.D., and graduate student Donna Cvetkovic describe new findings about kisspeptins. while they usually prevent the spread of cancer, kisspeptins actally make some breast cancers worse, with... Click here for more information. KISS 1 is a metastasis-suppressor gene which helps to prevent the spread of cancers, including melanoma, pancreatic and ovarian cancers to name a few. But new research from Western University's Schulich School of Medicine & ...

Fainting may run in families while triggers may not

2013-04-16
MINNEAPOLIS – New research suggests that fainting may be genetic and, in some families, only one gene may be responsible. However, a predisposition to certain triggers, such as emotional distress or the sight of blood, may not be inherited. The study is published in the April 16, 2013, print issue of Neurology®, the medical journal of the American Academy of Neurology. Fainting, also called vasovagal syncope, is a brief loss of consciousness when your body reacts to certain triggers. It affects at least one out of four people. "Our study strengthens the evidence that ...

Researchers discover biomarker for devastating intestinal disease found in early preterm infants

2013-04-16
Researchers have discovered a biomarker that may help prevent a devastating intestinal disease that occurs in one of every 10 early preterm infants. The Cincinnati Children's Hospital Medical Center study may help prevent necrotizing enterocolitis (NEC), a condition primarily seen in preemies in which bowel tissue dies. The death rate approaches 30 percent. Survivors are at risk for short-bowel syndrome (caused by surgical removal of the small intestine) and neurodevelopmental disability. The study is published in the journal Microbiome. The research, led by Ardythe ...

Drinking cup of beetroot juice daily may help lower blood pressure

2013-04-16
A cup of beetroot juice a day may help reduce your blood pressure, according to a small study in the American Heart Association journal Hypertension. People with high blood pressure who drank about 8 ounces of beetroot juice experienced a decrease in blood pressure of about 10 mm Hg. But the preliminary findings don't yet suggest that supplementing your diet with beetroot juice benefits your health, researchers said. "Our hope is that increasing one's intake of vegetables with a high dietary nitrate content, such as green leafy vegetables or beetroot, might be a lifestyle ...

Patients go undercover to record encounters with doctors

2013-04-16
Patients' health outcomes improve when physicians individualize care and take their patients' life circumstances into account, according to a new study by the University of Illinois at Chicago and the U.S. Department of Veterans Affairs. The study is the largest ever to be conducted using real patients to collect data about their doctors' behavior using concealed audio recorders. It appears in the April 16 issue of Annals of Internal Medicine and was funded by the U.S. Department of Veterans Affairs. "What our study really tells us is that the information that patients ...

'Comparison shopping' by doctors saves money

2013-04-16
Research at Johns Hopkins suggests that if hospitals would show physicians the price of some diagnostic laboratory tests at the time the tests are ordered, doctors would order substantially fewer of them or search for lower-priced alternatives. In a study of up-front price transparency at The Johns Hopkins Hospital, the researchers found that the practice of offering price information decreased overall use of tests by roughly 9 percent. Currently, hospitals typically keep both patients and providers essentially blind to the cost of medical services, a system that wastefully ...

Concert cacophony: Short-term hearing loss protective, not damaging

2013-04-16
Contrary to conventional wisdom, short-term hearing loss after sustained exposure to loud noise does not reflect damage to our hearing: instead, it is the body's way to cope. The landmark finding could lead to improved protection against noise-induced hearing loss in future. The research, led by University of New South Wales Professor Gary Housley, has found that "reversible hearing loss" is a physiological adaptation mechanism, allowing the cochlea (the auditory portion of the inner ear) to perform normally when exposed to noise stress. "This explains why we lose ...

LAST 30 PRESS RELEASES:

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

[Press-News.org] New study finds digoxin safe despite recent reports
Evidence lacking that digoxin increases mortality